Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Hepatology. 2014 Feb 18;59(4):1435–1447. doi: 10.1002/hep.26790

Figure 1. Tumor hypoxia and SDF1α expression are increased after sorafenib treatment in orthotopic HCC.

Figure 1

A, Representative immunofluorescence staining of CAIX and SDF1α in HCA-1 tumor implanted in mice with liver fibrosis. Images are 636μm across. B,C, The hypoxic tumor tissue fraction (B) and SDF1α expression (C) increased significantly after sorafenib treatment in orthotopic HCA-1 tumors in mice (n=5–9). D, Immunofluorescence imaging analysis showed that SDF1α expression is increased after 14 days of sorafenib treatment in spontaneous HCCs in Mst1−/− Mst2F/− transgenic mice. The increased hypoxia and SDF1α expression persisted when sorafenib treatment was combined with AMD3100 (n=5–9). E,F, Expression of CAIX (E) and SDF1α (F) in the liver was not significantly changed after sorafenib, AMD3100 or combination treatment (n=4–7). The number of random regions of interest used for quantification is shown in parentheses. Data are presented as mean ± SEM; *P<0.05, **P<0.01.